Edition:
United States

Cytokinetics Inc (CYTK.OQ)

CYTK.OQ on NASDAQ Stock Exchange Global Select Market

8.40USD
15 Dec 2017
Change (% chg)

$0.40 (+5.00%)
Prev Close
$8.00
Open
$8.05
Day's High
$8.45
Day's Low
$8.00
Volume
1,037,717
Avg. Vol
178,617
52-wk High
$17.20
52-wk Low
$7.00

Latest Key Developments (Source: Significant Developments)

Cytokinetics Inc announces negative results from VITALITY-ALS
Tuesday, 21 Nov 2017 07:30am EST 

Nov 21 (Reuters) - Cytokinetics Inc :Cytokinetics announces negative results from VITALITY-ALS.Phase 3 clinical trial of Tirasemtiv in patients with ALS did not meet primary or secondary endpoints​.No new safety or tolerability findings related to Tirasemtiv were identified in VITALITY-ALS​.Believe that limitations of Tirasemtiv may be addressed with co's next-generation fast skeletal muscle activator, CK-2127107​.Have decided to suspend development of Tirasemtiv​.Limitations of Tirasemtiv may be addressed with co's "next-generation fast" skeletal muscle activator, CK-2127107​.Believe CK-2127107 will be better tolerated, potentially more effective than Tirasemtiv for ALS & look forward to phase 2 results in 2018​.  Full Article

Cytokinetics enters into second amendment to certain loan and security agreement
Tuesday, 31 Oct 2017 04:32pm EDT 

Oct 31 (Reuters) - Cytokinetics Inc ::Cytokinetics - ‍on Oct 27, entered into second amendment to certain loan and security agreement dated as of October 19, 2015 .Cytokinetics - ‍original loan agreement, as amended by amendment, provides for secured growth capital term loans of up to $50.0 million​.  Full Article

Cytokinetics reports Q3 loss of ‍$0.60/shr​
Thursday, 26 Oct 2017 04:00pm EDT 

Oct 26 (Reuters) - Cytokinetics Inc :Cytokinetics, Inc. reports third quarter 2017 financial results.Q3 revenue $6.2 million versus I/B/E/S view $6.5 million.Cytokinetics Inc - qtrly loss per share ‍$0.60​.Cytokinetics Inc- ‍anticipates cash research and development expenses will be in range of $103 million to $107 million for 2017​.  Full Article

Cytokinetics announces dosing of first patient in Japan in phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure
Tuesday, 19 Sep 2017 07:30am EDT 

Sept 19 (Reuters) - Cytokinetics Inc :Cytokinetics announces dosing of first patient in Japan in GALACTIC-HF, phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure.Cytokinetics - ‍pharmacokinetics, pharmacodynamics, safety, tolerability data from trial were consistent with previously reported results from COSMIC-HF​.Cytokinetics Inc - ‍ coincident with patient dosing in galactic-hf, Amgen will make a $10 million milestone payment to Cytokinetics​.  Full Article

Cytokinetics Q2 loss per share $0.60
Wednesday, 2 Aug 2017 04:00pm EDT 

Aug 2 (Reuters) - Cytokinetics Inc :Cytokinetics Inc reports second quarter 2017 financial results.Q2 revenue $3.1 million versus $5.8 million.Q2 loss per share $0.60.Q2 revenue view $8.3 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view $-0.57 -- Thomson Reuters I/B/E/S.  Full Article

Cytokinetics announces positive results from phase 2 trial of Omecamtiv Mecarbil
Wednesday, 2 Aug 2017 07:30am EDT 

Aug 2 (Reuters) - Cytokinetics Inc ::Cytokinetics announces positive results from phase 2 clinical trial of Omecamtiv Mecarbil in Japanese patients with heart failure.Cytokinetics announces positive results from phase 2 clinical trial of Omecamtiv Mecarbil in Japanese patients with heart failure.Cytokinetics inc - ‍company is eligible to earn $10 million milestone payment from amgen upon first patient dosing in Japan in phase 3 outcomes trial​.Cytokinetics inc - ‍phase 2 clinical trial of Omecamtiv Mecarbil in Japanese patients with heart failure has met its pharmacokinetic primary endpoint​.Cytokinetics inc - ‍phase 2 clinical trial demonstrated statistically significant improvements in systolic ejection time (set), a secondary endpoint​.Cytokinetics inc - ‍cytokinetics is eligible to earn a $10 million milestone payment from amgen upon first dosing of a patient in Japan in Galactic-Hf​.  Full Article

Cytokinetics announces start of FORTITUDE-ALS
Thursday, 27 Jul 2017 07:30am EDT 

July 27 (Reuters) - Cytokinetics Inc :Cytokinetics announces start of fortitude-als, a phase 2 clinical trial of ck-2127107 in patients with amyotrophic lateral sclerosis.  Full Article

Cytokinetics reports baseline data from first cohort of phase 2 clinical trial of ck-2127107 in patients with SMA
Wednesday, 5 Jul 2017 07:30am EDT 

July 5 (Reuters) - Cytokinetics Inc ::Cytokinetics announces baseline data from first cohort of phase 2 clinical trial of ck-2127107 in patients with sma.Cytokinetics -screen failures in cohort 1 primarily due to hfmse score that was either too high in ambulatory patients or too low in non-ambulatory patients.Cytokinetics - there were no statistically significant differences otherwise in baseline demographics of enrolled patients compared to screen failures.Cytokinetics - screen failures in cohort 1 primarily due to hfmse score that was either too high in ambulatory patients or too low in non-ambulatory patients.  Full Article

Cytokinetics says Ching Jaw joined co as senior vice president, CFO on June 26, 2017
Thursday, 29 Jun 2017 04:50pm EDT 

June 29 (Reuters) - Cytokinetics Inc :Cytokinetics Inc says Ching Jaw joined Cytokinetics as senior vice president, chief financial officer on june 26, 2017 - sec filing.  Full Article

Cytokinetics starts phase 1B clinical trial of CK-2127107 in elderly subjects
Thursday, 29 Jun 2017 07:30am EDT 

June 29 (Reuters) - Cytokinetics Inc :Cytokinetics announces start of phase 1B clinical trial of CK-2127107 in elderly subjects with limited mobility.Cytokinetics Inc - clinical trial is expected to enroll at least 60 subjects in United States who are 70 to 89 years of age with limited mobility.  Full Article

Cytokinetics sinks on abandoning ALS drug after failed trial

Cytokinetics Inc shares plummeted nearly 28 percent on Tuesday after the drugmaker said it would stop developing one of its treatments for ALS, a fatal neuro-degenerative disorder, after the drug failed to improve lung function in a key trial.